TNF-alpha inhibitors for ankylosing spondylitis
Objectives: To assess the benefit and harms of adalimumab, etanercept, golimumab, and infliximab (TNF-alpha inhibitors) in peoplewith ankylosing spondylitis.
Search methods: We searched the following databases to January 26, 2009: MEDLINE (from 1966); EMBASE (from 1980); the Cochrane Central Register of Controlled Trials (CENTRAL; 2008, Issue 4); ACP Journal Club; CINAHL (from1982); and ISIWeb of Knowledge (from 1900). We ran updated searches in May 2012, October 2013, and in June 2014 for McMaster PLUS. We searched major regulatory agencies for safety warnings and clinicaltrials. gov for registered trials.
Selection criteria: Randomized controlled trials (RCTs) comparing adalimumab, etanercept, golimumab and infliximab to placebo, other drugs or usual care in patients with ankylosing spondylitis, reported in abstract or full-text.
Data collection and analysis: Two authors independently assessed search results, risk of bias, and extracted data. We conducted Bayesian mixed treatment comparison (MTC) meta-analyses using WinBUGS software. To investigate a class-effect of harms across biologics, we pooled harms data using Review Manager 5.
History
Publication title
Cochrane Database of Systematic ReviewsIssue
4Article number
CD005468Number
CD005468Pagination
1-145ISSN
1469-493XDepartment/School
Menzies Institute for Medical ResearchPublisher
John Wiley & Sons Ltd.Place of publication
United KingdomRights statement
Copyright 2015 The Cochrane CollaborationRepository Status
- Open